ArticleJournal of endocrinological investigation2026
Liver fibrosis risk: a silent threat in type 1 diabetes mellitus.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMetabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized; however, its relevance in individuals with type 1 diabetes mellitus (T1DM) remains unclear. This study aimed to investigate MASLD and its associated determinants in patients with T1DM using multiparametric liver ultrasonography and noninvasive scoring indices.
methodsThis study included 43 patients with T1DM and 43 age-, gender-, and BMI-matched controls. Noninvasive steatosis and fibrosis indices were calculated. Multiparametric liver US, including liver stiffness, attenuation imaging, texture, and hepatorenal index, was used to evaluate steatosis and fibrosis.
resultsSteatosis prevalence did not differ between patients with T1DM and controls; however, both FIB-4 index and liver stiffness measurement (LSM) defined risk of liver fibrosis were significantly higher in the T1DM group (11.6% vs. 2.3%). Among patients with T1DM, those with LSM ≥ 8.0 kPa had higher FIB-4 index and hsCRP levels and more frequent retinopathy (p < 0.05). FIB-4 index demonstrated good diagnostic performance for detecting LSM-defined liver fibrosis risk (AUC = 0.86), with an optimal threshold of 0.98. hsCRP levels correlated significantly with LSM (r = 0.410, P = 0.034).
conclusionsWe demonstrated a modest increase in liver fibrosis risk in patients with T1DM compared with controls, independent of steatosis. Lower FIB-4 cut-off values may improve sensitivity for detecting liver fibrosis in T1DM, and higher hsCRP levels in patients with LSM ≥ 8 kPa suggest an possible inflammatory contribution to fibrogenesis, supporting the clinical value of noninvasive fibrosis assessment in T1DM.
Indexed as
Identifiers
42566182What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.